Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Abstract

Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression. However, as with any new treatment, it was unclear how this efficacy would translate into real‐world clinical practice. The objective of this study was to systematically collate the published real‐world clinical effectiveness data for ocrelizumab in relapsing remitting multiple sclerosis and primary progressive multiple sclerosis. A search strategy was developed in MEDLINE and Embase to identify articles reporting real‐world evidence in people with relapsing remitting multiple sclerosis or primary progressive multiple sclerosis receiving treatment with ocrelizumab. The search focused on English language articles only but was not limited by the country in which the study was conducted or the time frame of the study. Additional manual searches of relevant websites were also performed. Fifty‐two studies were identified reporting relevant evidence. Real‐world effectiveness data for ocrelizumab were consistently favorable, with reductions in relapse rate and disease progression rates similar to those reported in the OPERA I/OPERA II and ORATORIO clinical trials, including in studies with more diverse patient populations not well represented in the pivotal trials. Although direct comparisons are confounded by lack of randomization of treatments, outcomes reported suggest that ocrelizumab has a similar or greater efficacy than other therapy options. Initial real‐world effectiveness data for ocrelizumab appear favorable and consistent with results reported in clinical trials, providing clinicians with an efficacious option to treat patients with multiple sclerosis.

Ocrelizumab for the treatment of relapsing remitting multiple sclerosis: A cost effectiveness study in Peru

“…These ndings are consistent with our study and further emphasize the cost-effectiveness of Ocrelizumab in the treatment of RRMS. Furthermore, studies by Montalban et al [21], Ayati et al [22], and Versteegh et al [23] evaluated the realworld cost-effectiveness of Ocrelizumab and demonstrated its value in terms of improved outcomes and cost savings. They found that Ocrelizumab was associated with better clinical outcomes, including reduced relapse rates and improved disability progression, while also providing economic bene ts.…”

Neuroborreliosis in a patient with Multiple Sclerosis on Ocrelizumab, a case report

“…Ocrelizumab is an FDA-approved CD20-depleting therapy with remarkable e cacy against active MS and a favorable way of administration every six months (Montalban et al, 2023). Since it is a relatively new treatment option in the market, it is important to understand its safety pro le.…”